Cytosorbents (CTSO) Operating Leases (2018 - 2026)

Cytosorbents' Operating Leases history runs 9 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• Quarterly Operating Leases fell 4.58% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (down 4.58% YoY) and the FY2025 annual result came in at $11.9 million, down 4.35% from the prior year.
• Operating Leases was $11.8 million for Q1 2026 at Cytosorbents, down from $11.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $13.5 million in Q2 2022 and bottomed at $11.8 million in Q1 2026.
• A 5-year average of $12.7 million and a median of $12.9 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases soared 1325.64% — and 2025, when it dropped 6.57%.
• Cytosorbents' Operating Leases stood at $13.1 million in 2022, then declined by 1.87% to $12.9 million in 2023, then dropped by 3.51% to $12.4 million in 2024, then declined by 4.35% to $11.9 million in 2025, then declined by 1.27% to $11.8 million in 2026.
• Business Quant data shows CTSO's Operating Leases at $11.8 million in Q1 2026, $11.9 million in Q4 2025, and $12.1 million in Q3 2025.